Welcome!

News Feed Item

Sickle Cell Disease Global Clinical Trials Review, H2, 2014

LONDON, Sept. 1, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Sickle Cell Disease Global Clinical Trials Review, H2, 2014

https://www.reportbuyer.com/product/689745/Sickle-Cell-Disease-Global-Clinical-Trials-Review-H2-2014.html

Sickle Cell Disease Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Sickle Cell Disease Global Clinical Trials Review, H2, 2014" provides data on the Sickle Cell Disease clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Sickle Cell Disease. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Sickle Cell Disease. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2

List of Tables 4
List of Figures 5
Introduction 6
Sickle Cell Disease 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Sickle Cell Disease to Hematological Disorders Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Sickle Cell Disease to Hematological Disorders Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Sickle Cell Disease 25
Subjects Recruited Over a Period of Time 30
Clinical Trials by Sponsor Type 31
Prominent Sponsors 32
Top Companies Participating in Sickle Cell Disease Therapeutics Clinical Trials 33
Prominent Drugs 35
Latest Clinical Trials News on Sickle Cell Disease 36
Jun 16, 2014: Mast Therapeutics Initiates Sub-Study Within Phase 3 EPIC Trial 36
Clinical Trial Profiles 37
Clinical Trial Overview of Top Companies 37
Novartis AG 37
Clinical Trial Overview of Novartis AG 37
Eli Lilly and Company 38
Clinical Trial Overview of Eli Lilly and Company 38
Pfizer Inc. 39
Clinical Trial Overview of Pfizer Inc. 39
Prolong Pharmaceuticals 40
Clinical Trial Overview of Prolong Pharmaceuticals 40
HemaQuest Pharmaceuticals, Inc. 41
Clinical Trial Overview of HemaQuest Pharmaceuticals, Inc. 41
Selexys Pharmaceuticals Corporation 42
Clinical Trial Overview of Selexys Pharmaceuticals Corporation 42
Ikaria Inc. 43
Clinical Trial Overview of Ikaria Inc. 43
Emmaus Life Sciences, Inc. 44
Clinical Trial Overview of Emmaus Life Sciences, Inc. 44
Baxter International Inc. 45
Clinical Trial Overview of Baxter International Inc. 45
Clinical Trial Overview of Top Institutes / Government 46
National Heart, Lung, and Blood Institute 46
Clinical Trial Overview of National Heart, Lung, and Blood Institute 46
Assistance Publique - Hopitaux de Paris 49
Clinical Trial Overview of Assistance Publique - Hopitaux de Paris 49
HaEmek Medical Center 50
Clinical Trial Overview of HaEmek Medical Center 50
Cincinnati Children's Hospital Medical Center 51
Clinical Trial Overview of Cincinnati Children's Hospital Medical Center 51
Duke University 52
Clinical Trial Overview of Duke University 52
Emory University 53
Clinical Trial Overview of Emory University 53
National Institutes of Health Clinical Center 54
Clinical Trial Overview of National Institutes of Health Clinical Center 54
Baylor College of Medicine 55
Clinical Trial Overview of Baylor College of Medicine 55
Children's Hospital & Research Center Oakland 56
Clinical Trial Overview of Children's Hospital & Research Center Oakland 56
Five Key Clinical Profiles 57
Appendix 99
Abbreviations 99
Definitions 99
Research Methodology 100
Secondary Research 101
About GlobalData 101
Contact Us 101
Disclaimer 101
Source 102

List of Tables
Sickle Cell Disease Therapeutics, Global, Clinical Trials by Region, 2014* 7
Sickle Cell Disease Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Sickle Cell Disease Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Sickle Cell Disease Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Sickle Cell Disease Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Sickle Cell Disease Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Sickle Cell Disease Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2014* 13
Sickle Cell Disease Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014* 14
Proportion of Sickle Cell Disease to Hematological Disorders Clinical Trials, G7 Countries (%), 2014* 15
Sickle Cell Disease Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Sickle Cell Disease Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Sickle Cell Disease to Hematological Disorders Clinical Trials, E7 Countries (%), 2014* 18
Sickle Cell Disease Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Sickle Cell Disease Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Sickle Cell Disease Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Sickle Cell Disease Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Sickle Cell Disease Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Sickle Cell Disease Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Sickle Cell Disease Therapeutics, Global, Suspended Clinical Trials, 2014* 25
Sickle Cell Disease Therapeutics, Global, Withdrawn Clinical Trials, 2014* 26
Sickle Cell Disease Therapeutics, Global, Terminated Clinical Trials, 2014* 27
Sickle Cell Disease Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 30
Sickle Cell Disease Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 31
Sickle Cell Disease Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 32
Sickle Cell Disease Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 34
Sickle Cell Disease Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 35
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014* 37
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Eli Lilly and Company, 2014* 38
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014* 39
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Prolong Pharmaceuticals, 2014* 40
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by HemaQuest Pharmaceuticals, Inc., 2014* 41
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Selexys Pharmaceuticals Corporation, 2014* 42
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Ikaria Inc., 2014* 43
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Emmaus Life Sciences, Inc., 2014* 44
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Baxter International Inc., 2014* 45
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by National Heart, Lung, and Blood Institute, 2014* 46
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Assistance Publique - Hopitaux de Paris, 2014* 49
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by HaEmek Medical Center, 2014* 50
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Cincinnati Children's Hospital Medical Center, 2014* 51
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Duke University, 2014* 52
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Emory University, 2014* 53
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by National Institutes of Health Clinical Center, 2014* 54
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Baylor College of Medicine, 2014* 55
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Children's Hospital & Research Center Oakland, 2014* 56

List of Figures
Sickle Cell Disease Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Sickle Cell Disease Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Sickle Cell Disease Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Sickle Cell Disease Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Sickle Cell Disease Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Sickle Cell Disease Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Sickle Cell Disease Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2014* 13
Sickle Cell Disease Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014* 14
Proportion of Sickle Cell Disease to Hematological Disorders Clinical Trials, G7 Countries (%), 2014* 15
Sickle Cell Disease Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Sickle Cell Disease Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Sickle Cell Disease to Hematological Disorders Clinical Trials, E7 Countries (%), 2014* 18
Sickle Cell Disease Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Sickle Cell Disease Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Sickle Cell Disease Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Sickle Cell Disease Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Sickle Cell Disease Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Sickle Cell Disease Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Sickle Cell Disease Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 30
Sickle Cell Disease Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 31
Sickle Cell Disease Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 32
Sickle Cell Disease Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 33
Sickle Cell Disease Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 35
GlobalData Methodology 100

Read the full report:
Sickle Cell Disease Global Clinical Trials Review, H2, 2014

https://www.reportbuyer.com/product/689745/Sickle-Cell-Disease-Global-Clinical-Trials-Review-H2-2014.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
In his keynote at 18th Cloud Expo, Andrew Keys, Co-Founder of ConsenSys Enterprise, provided an overview of the evolution of the Internet and the Database and the future of their combination – the Blockchain. Andrew Keys is Co-Founder of ConsenSys Enterprise. He comes to ConsenSys Enterprise with capital markets, technology and entrepreneurial experience. Previously, he worked for UBS investment bank in equities analysis. Later, he was responsible for the creation and distribution of life settle...
Is advanced scheduling in Kubernetes achievable?Yes, however, how do you properly accommodate every real-life scenario that a Kubernetes user might encounter? How do you leverage advanced scheduling techniques to shape and describe each scenario in easy-to-use rules and configurations? In his session at @DevOpsSummit at 21st Cloud Expo, Oleg Chunikhin, CTO at Kublr, answered these questions and demonstrated techniques for implementing advanced scheduling. For example, using spot instances and co...
Blockchain. A day doesn’t seem to go by without seeing articles and discussions about the technology. According to PwC executive Seamus Cushley, approximately $1.4B has been invested in blockchain just last year. In Gartner’s recent hype cycle for emerging technologies, blockchain is approaching the peak. It is considered by Gartner as one of the ‘Key platform-enabling technologies to track.’ While there is a lot of ‘hype vs reality’ discussions going on, there is no arguing that blockchain is b...
DevOps is under attack because developers don’t want to mess with infrastructure. They will happily own their code into production, but want to use platforms instead of raw automation. That’s changing the landscape that we understand as DevOps with both architecture concepts (CloudNative) and process redefinition (SRE). Rob Hirschfeld’s recent work in Kubernetes operations has led to the conclusion that containers and related platforms have changed the way we should be thinking about DevOps and...
The need for greater agility and scalability necessitated the digital transformation in the form of following equation: monolithic to microservices to serverless architecture (FaaS). To keep up with the cut-throat competition, the organisations need to update their technology stack to make software development their differentiating factor. Thus microservices architecture emerged as a potential method to provide development teams with greater flexibility and other advantages, such as the abili...
Product connectivity goes hand and hand these days with increased use of personal data. New IoT devices are becoming more personalized than ever before. In his session at 22nd Cloud Expo | DXWorld Expo, Nicolas Fierro, CEO of MIMIR Blockchain Solutions, will discuss how in order to protect your data and privacy, IoT applications need to embrace Blockchain technology for a new level of product security never before seen - or needed.
Leading companies, from the Global Fortune 500 to the smallest companies, are adopting hybrid cloud as the path to business advantage. Hybrid cloud depends on cloud services and on-premises infrastructure working in unison. Successful implementations require new levels of data mobility, enabled by an automated and seamless flow across on-premises and cloud resources. In his general session at 21st Cloud Expo, Greg Tevis, an IBM Storage Software Technical Strategist and Customer Solution Architec...
Coca-Cola’s Google powered digital signage system lays the groundwork for a more valuable connection between Coke and its customers. Digital signs pair software with high-resolution displays so that a message can be changed instantly based on what the operator wants to communicate or sell. In their Day 3 Keynote at 21st Cloud Expo, Greg Chambers, Global Group Director, Digital Innovation, Coca-Cola, and Vidya Nagarajan, a Senior Product Manager at Google, discussed how from store operations and ...
"As we've gone out into the public cloud we've seen that over time we may have lost a few things - we've lost control, we've given up cost to a certain extent, and then security, flexibility," explained Steve Conner, VP of Sales at Cloudistics,in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
Blockchain is a shared, secure record of exchange that establishes trust, accountability and transparency across business networks. Supported by the Linux Foundation's open source, open-standards based Hyperledger Project, Blockchain has the potential to improve regulatory compliance, reduce cost as well as advance trade. Are you curious about how Blockchain is built for business? In her session at 21st Cloud Expo, René Bostic, Technical VP of the IBM Cloud Unit in North America, discussed the b...
The use of containers by developers -- and now increasingly IT operators -- has grown from infatuation to deep and abiding love. But as with any long-term affair, the honeymoon soon leads to needing to live well together ... and maybe even getting some relationship help along the way. And so it goes with container orchestration and automation solutions, which are rapidly emerging as the means to maintain the bliss between rapid container adoption and broad container use among multiple cloud host...
In his session at 21st Cloud Expo, Michael Burley, a Senior Business Development Executive in IT Services at NetApp, described how NetApp designed a three-year program of work to migrate 25PB of a major telco's enterprise data to a new STaaS platform, and then secured a long-term contract to manage and operate the platform. This significant program blended the best of NetApp’s solutions and services capabilities to enable this telco’s successful adoption of private cloud storage and launching ...
You know you need the cloud, but you’re hesitant to simply dump everything at Amazon since you know that not all workloads are suitable for cloud. You know that you want the kind of ease of use and scalability that you get with public cloud, but your applications are architected in a way that makes the public cloud a non-starter. You’re looking at private cloud solutions based on hyperconverged infrastructure, but you’re concerned with the limits inherent in those technologies.
Imagine if you will, a retail floor so densely packed with sensors that they can pick up the movements of insects scurrying across a store aisle. Or a component of a piece of factory equipment so well-instrumented that its digital twin provides resolution down to the micrometer.
"Since we launched LinuxONE we learned a lot from our customers. More than anything what they responded to were some very unique security capabilities that we have," explained Mark Figley, Director of LinuxONE Offerings at IBM, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.